CA2472151A1 - Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound - Google Patents

Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound Download PDF

Info

Publication number
CA2472151A1
CA2472151A1 CA002472151A CA2472151A CA2472151A1 CA 2472151 A1 CA2472151 A1 CA 2472151A1 CA 002472151 A CA002472151 A CA 002472151A CA 2472151 A CA2472151 A CA 2472151A CA 2472151 A1 CA2472151 A1 CA 2472151A1
Authority
CA
Canada
Prior art keywords
treatment
allergic disease
composition according
omalizumab
ige antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002472151A
Other languages
English (en)
French (fr)
Inventor
Charles Edward Owen
Howard George Fox
Christoph Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2472151A1 publication Critical patent/CA2472151A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002472151A 2002-01-09 2003-01-09 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound Abandoned CA2472151A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0200429.9 2002-01-09
GBGB0200429.9A GB0200429D0 (en) 2002-01-09 2002-01-09 Organic compounds
PCT/EP2003/000154 WO2003057249A1 (en) 2002-01-09 2003-01-09 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound

Publications (1)

Publication Number Publication Date
CA2472151A1 true CA2472151A1 (en) 2003-07-17

Family

ID=9928810

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002472151A Abandoned CA2472151A1 (en) 2002-01-09 2003-01-09 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound

Country Status (9)

Country Link
US (2) US20050042215A1 (cg-RX-API-DMAC7.html)
EP (1) EP1465662A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005514414A (cg-RX-API-DMAC7.html)
CN (1) CN1612751A (cg-RX-API-DMAC7.html)
AU (1) AU2003210153A1 (cg-RX-API-DMAC7.html)
BR (1) BR0306732A (cg-RX-API-DMAC7.html)
CA (1) CA2472151A1 (cg-RX-API-DMAC7.html)
GB (1) GB0200429D0 (cg-RX-API-DMAC7.html)
WO (1) WO2003057249A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512946A (ja) * 2001-05-09 2005-05-12 ノバルティス アクチエンゲゼルシャフト 選択的免疫調節法
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
JP2007505932A (ja) * 2003-09-18 2007-03-15 マクサイト, インコーポレイテッド 経強膜送達
WO2005030331A1 (en) * 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Combination antihistamine medication
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
GB0502358D0 (en) * 2005-02-04 2005-03-16 Novartis Ag Organic compounds
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
KR101478164B1 (ko) 2006-02-09 2014-12-31 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
WO2008099188A1 (en) * 2007-02-15 2008-08-21 Astrazeneca Ab Binding members for ige molecules
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
EP3708188A4 (en) * 2017-11-07 2021-12-01 HuBit genomix, Inc. METHOD FOR INHIBITING THE ACQUISITION OF AN ALLERGIC PREDISPOSITION IN THE INFANT PHASE BY SUPPRESSING IGE CLASS-SPECIFIC IMMUNE-REACTIVITY
CA3094749A1 (en) * 2018-03-26 2019-10-03 Novartis Ag Methods of treating chronic spontaneous urticaria using ligelizumab
CN114504644B (zh) * 2021-12-24 2024-02-13 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
JP2003524602A (ja) * 1998-09-18 2003-08-19 ダイナバックス テクノロジーズ コーポレイション IgE関連疾患の治療方法と、その治療において使用する組成物
GB0012383D0 (en) * 2000-05-22 2000-07-12 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP2005514414A (ja) 2005-05-19
GB0200429D0 (en) 2002-02-27
EP1465662A1 (en) 2004-10-13
US20050042215A1 (en) 2005-02-24
WO2003057249A1 (en) 2003-07-17
US20060240000A1 (en) 2006-10-26
CN1612751A (zh) 2005-05-04
AU2003210153A1 (en) 2003-07-24
BR0306732A (pt) 2004-12-28

Similar Documents

Publication Publication Date Title
US20060240000A1 (en) Combination treatments for allergic disease comprising administering an anti-IgE antibody and antiallergic compound
Lane et al. Treatment of recalcitrant atopic dermatitis with omalizumab
US20080206237A1 (en) Synergistic Combination Of Xolair/Omalizumab/E25 With Immunosuppressive Agent
Rafferty et al. Terfenadine (Seldane®) is a potent and selective histamine H1 receptor antagonist in asthmatic airways
JP5411504B2 (ja) 薬物嗜癖および行動嗜癖を治療するためのイブジラストの使用
JP2004529180A (ja) IgE関連障害を処置するのに使用するための組成物
Johnson et al. A review of respiratory biologic agents in severe asthma
CA2901421A1 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
CA2962944A1 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
WO2004067006A1 (en) Combination of a pde iv inhibitor and a tnf-alpha antagonist
JP2005514414A5 (cg-RX-API-DMAC7.html)
EP4531856B1 (en) Bruton's kinase inhibitors for the treatment of a sudden allergic reaction
WO2021255621A1 (en) Treatment of food allergy using anti-ige antibodies
EP4199922B1 (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
EP3376869B1 (en) Treatment of autoimmune disease
KR20190024572A (ko) TNFα 관련 질환을 치료하기 위한 피하 투여 요법
KR100756974B1 (ko) 알레르기 질환 및 만성염증성 질환의 치료를 위한 약학적 조성물 및 키트
AU2021293980B2 (en) Treatment of food allergy using anti-IgE antibodies
EP3903778B1 (en) Immunosuppressive pharmaceutical composition and application thereof
WO2006098607A1 (en) Histamine-containing composition for the treatment of allergic diseases
JP2015500278A (ja) Trpa1アンタゴニストと抗コリン剤とを含む医薬組成物
HK40091313A (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
HK40091313B (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
Saco et al. Biologics in allergic disease
Calix Modell's Drugs in Current Use and New Drugs, 2006

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued